Simdax
Simdax contains levosimendan, a calcium sensitizer and potassium channel opener. It increases cardiac contractility by binding to cardiac troponin C in a calcium-dependent manner, and induces vasodilation by opening ATP-sensitive potassium channels in vascular smooth muscle. This dual mechanism increases cardiac output and reduces both preload and afterload without significantly increasing myocardial oxygen consumption.
Dosage by Body Weight
For intravenous use only. Must be diluted before administration. The standard regimen is a loading dose of 6-12 mcg/kg infused over 10 minutes, followed by a continuous maintenance infusion of 0.1 mcg/kg/min. The maintenance rate can be decreased to 0.05 mcg/kg/min or increased to 0.2 mcg/kg/min based on patient hemodynamic response and tolerance.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy in pediatric patients have not been established. Use is restricted to adults.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy in pediatric patients have not been established. Use is restricted to adults.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy in pediatric patients have not been established. Use is restricted to adults.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy in pediatric patients have not been established. Use is restricted to adults.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy in pediatric patients have not been established. Use is restricted to adults.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | Not applicable | Safety and efficacy in pediatric patients have not been established. Use is restricted to adults. |
| 5-7 kg | Not recommended | Not applicable | Safety and efficacy in pediatric patients have not been established. Use is restricted to adults. |
| 8-10 kg | Not recommended | Not applicable | Safety and efficacy in pediatric patients have not been established. Use is restricted to adults. |
| 11-15 kg | Not recommended | Not applicable | Safety and efficacy in pediatric patients have not been established. Use is restricted to adults. |
| 16-20 kg | Not recommended | Not applicable | Safety and efficacy in pediatric patients have not been established. Use is restricted to adults. |
Formulation
Purpose
Short-term treatment of acutely decompensated severe chronic heart failure (ADHF) in situations where conventional therapy is not sufficient, and where inotropic support is considered appropriate.
Generic Name
LevosimendanScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.